Chaim Lebovits

CHIEF EXECUTIVE OFFICER
Chaim Lebovits joined Cell-Gene company in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States. In the last two years, Mr. Lebovits has played a pivotal role in bringing additional strength and depth to the Cell-Gene company executive team, recruiting a number of biotech executives with critical clinical development and path-to-market experience to support the phase 3 development and regulatory filing of autologous MSC-NTF cells in ALS and MS.
In addition to his biotech experience, Mr. Lebovits is a senior executive on the board of a number of public and private companies involved in natural resource exploration projects around the world.
Scroll to Top

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.